Table 3.

Multivariable adjusted^* rates of hospitalised infection and associated rate differences for biological-free low and high-risk patient subgroups

		Infection rate difference† compared with infliximab among biological-free patients (rate per 100 patient-years)
	Adjusted* HR (95% CI)	Low‡ baseline infection risk	High‡ baseline infection risk
Infliximab	1.0 (referent)	Referent	Referent
Abatacept	0.68 (0.48 to 0.96)	−1.5	−7.9
Adalimumab	0.52 (0.39 to 0.71)	−2.1	−8.2
Etanercept	0.64 (0.49 to 0.84)	−1.3	−5.4
Rituximab	0.81 (0.55 to 1.20)	−0.8	6.4
Infection risk score
Quintile 1	1.0 (referent)
Quintile 2	1.19 (0.73 to 1.92)
Quintile 3	2.04 (1.31 to 3.18)
Quintile 4	3.08 (2.03 to 4.67)
Quintile 5	5.28 (3.54 to 7.88)

^*Results were adjusted for biological-free vs switcher status and quintile of the infection risk score. The infection risk score included factors associated with infection as described in the supplementary appendix. The HR in this column reflect the same results as the ‘Combined’ results in figure 2.).

^†Negative numbers indicate a rate that is lower than the rate for infliximab.

^‡Low and high baseline infection risk was defined as patients with a predicted infection risk below and above 5.2 per 100 patient-years, respectively.